Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
May 2025 – Industry Events
What We Do
Respiratory
self-care
solutions
Our technology is focused on advancing Inhalation-Based Therapies for Respiratory Infections in Civilian and Defence Applications
Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
Dual-Use Platform
Introducing a transformative treatment form the worlds most prevalent disease in a 43bn€ market.
Civic
Providing a versatile and safe treatment and protection against future pandemics.
Crisis
Relief
Defence
Enhance military readiness by reducing downtime and misuse of antibiotics.
We’re LIIRA CARE
Redefining respiratory self-care
Redefining respiratory self-care
LIITA Care is a late-stage biotech company dedicated to the discovery and development of novel therapies that improve the lives of consumers suffering from respiratory diseases
Our mission is to become a global provider of the future go-to solution for respiratory self-care. We do this by transforming the cough and cold category with our portfolio of clinically documented over-the-counter treatments
Our patented technology deploys NaCl microparticles in a new and consumer-friendly treatment form proven to be clinically beneficial in diseases that affect more than 80% of the world's population
Our Product Pipeline
Diversified and innovative pipeline including late-stage assets open the opportunity for position as global go-to brand for NaCl particle inhalation
Latest News
Catch up on the latest news & updates here
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
Operational Context
Independent Research on Respiratory Risk in Military and High-Performance Populations
Airway infections account for 25–30% of infectious-disease hospitalizations and are the top cause of outpatient treatment in army personnel, with incidence up to three-fold civilian rates (Respiratory Physiology & Neurobiology)
Over 40% of military airway infection cases have unknown pathogens, complicating preventive efforts (Respiratory Physiology & Neurobiology)
Young adults experience 2.3–4.8 airway infection episodes annually (Ruuskanen et al., Journal of Infection)
High-intensity and endurance athletes report 2–3 airway infections per year, with acute symptom incidence up to 45% in cold-weather events and viral pathogens detected in up to 77% of symptomatic cases, underscoring diagnostic gaps in field settings (Ruuskanen et al., Journal of Infection)
Lower airway infections were the most burdensome AMR-related syndrome in 2019, causing over 1.5 million deaths globally (The Lancet, Global Burden of AMR, 2022)
Airway infections account for 25–30% of infectious-disease hospitalizations and are the top cause of outpatient treatment in army personnel, with incidence up to three-fold civilian rates (Respiratory Physiology & Neurobiology)
Over 40% of military airway infection cases have unknown pathogens, complicating preventive efforts (Respiratory Physiology & Neurobiology)
Young adults experience 2.3–4.8 airway infection episodes annually (Ruuskanen et al., Journal of Infection)
High-intensity and endurance athletes report 2–3 airway infections per year, with acute symptom incidence up to 45% in cold-weather events and viral pathogens detected in up to 77% of symptomatic cases, underscoring diagnostic gaps in field settings (Ruuskanen et al., Journal of Infection)
Lower airway infections were the most burdensome AMR-related syndrome in 2019, causing over 1.5 million deaths globally (The Lancet, Global Burden of AMR, 2022)
Clinical Evidence
Our Research on the role of NaCl-powered osmotic modulation in respiratory therapy
Hypertonic NaCl (1.2–1.5%) inhibits SARS-CoV-2 replication by 90–100% in Vero and Calu-3 cells (ACS Pharmacol Transl Sci) (PubMed)
NaCl depolarizes the plasma membrane, creating a low-energy state (high ADP/ATP ratio) without impairing mitochondria, disrupting the viral life cycle (ACS Pharmacol Transl Sci) (PubMed)
Maintains >70% cell viability at concentrations up to 210 mM, indicating a safe therapeutic window (ACS Pharmacol Transl Sci) (PubMed)
BREATHOX® inhalation (2 mg NaCl particles, 1–10 μm) administered 5×/day or 10×/day shortens time to cough resolution vs. standard care by day 10 (Journal of Clinical Medicine) (MDPI)
Combined BREATHOX® arms showed significantly faster cough resolution at day 10 (HR 2.10; 95% CI 1.20–3.67) with primarily mild, transient adverse events (Journal of Clinical Medicine) (MDPI)
Hypertonic NaCl (1.2–1.5%) inhibits SARS-CoV-2 replication by 90–100% in Vero and Calu-3 cells (ACS Pharmacol Transl Sci) (PubMed)
NaCl depolarizes the plasma membrane, creating a low-energy state (high ADP/ATP ratio) without impairing mitochondria, disrupting the viral life cycle (ACS Pharmacol Transl Sci) (PubMed)
Maintains >70% cell viability at concentrations up to 210 mM, indicating a safe therapeutic window (ACS Pharmacol Transl Sci) (PubMed)
BREATHOX® inhalation (2 mg NaCl particles, 1–10 μm) administered 5×/day or 10×/day shortens time to cough resolution vs. standard care by day 10 (Journal of Clinical Medicine) (MDPI)
Combined BREATHOX® arms showed significantly faster cough resolution at day 10 (HR 2.10; 95% CI 1.20–3.67) with primarily mild, transient adverse events (Journal of Clinical Medicine) (MDPI)
Breathox In Practice
Breathox® in Ukraine: Clinical & Operational Insights
Summary In 2024, LIITA donated 6,000 Breathox® units to 36 Ukrainian military units and healthcare facilities.
Dr. Christopher Clemmesen—Chief Consultant in Anesthesiology, military physician, and Director of Medical Affairs & Defense Health Strategy—reviewed field feedback.
Key Observations
Clinicians noted reduced coughing and overall symptom relief in soldiers and civilians (anecdotal).
Respiratory infections impair troop readiness, and antibiotic overuse risks resistance.
Breathox® ease symptoms and could potentially lessen antibiotic dependence.
Board member
Henrik Kjær Hansen
Novo Holdings
Board member
Jakob Ottesen Thiesson
Boston Consulting Group
Board member
Martin Røssberg
MR Law
CEO & Founder
Martin Ohrt
LIITA Care
CFO
Søren Kjær Henningsen
LIITA Care